https://www.selleckchem.com/pr....oducts/atuzabrutinib
This is the first study to evaluate the feasibility and acceptability of light therapy to reduce fatigue in AYA patients receiving cancer-directed therapy. These findings demonstrate the feasibility and acceptability of the intervention and provide preliminary evidence of the potential benefits of BWL, which warrants further study in a confirmatory efficacy trial. ClinicalTrials.gov Identifier Number NCT02429063. This is the first study to evaluate the feasibility and acceptability of light therapy to reduce fatigue in AYA patient
Like
Comment
Share
